KENDALL BOLTE: Open Payments
NPI 1215348388 · YORK, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$414 in 26 payments from 11 companies in 2025. Trend: 2023 $529 · 2024 $461 · 2025 $414
Food & beverage: $414
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 11 | $154 |
| Lilly USA, LLC | 4 | $61 |
| Novo Nordisk Inc | 2 | $35 |
| Astellas Pharma US Inc | 1 | $34 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $29 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| E.R. Squibb & Sons, L.L.C. | 1 | $19 |
| Seqirus USA Inc | 1 | $19 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $15 |
| GlaxoSmithKline, LLC. | 1 | $14 |
Products named: VRAYLAR, MOUNJARO, QULIPTA, Ozempic, Veozah, UBRELVY, Kerendia, REXULTI.
Industry payments across NE — which companies pay providers there.
